Kisqali FDA Approval History
FDA Approved: Yes (First approved March 13, 2017)
Brand name: Kisqali
Generic name: ribociclib
Dosage form: Tablets
Previous Name: LEE011
Company: Novartis Pharmaceuticals Corporation
Treatment for: Breast Cancer
Kisqali (ribociclib) is an inhibitor of cyclin-dependent kinase (CDK) 4 and 6 indicated for the combination treatment of pre/perimenopausal or postmenopausal women with HR+/HER2- metastatic breast cancer.
Development timeline for Kisqali
| Date | Article |
|---|---|
| Jul 18, 2018 | Approval Kisqali (ribociclib) Approved for Additional Indications in HR+/HER2- Advanced Breast Cancer |
| Mar 13, 2017 | Approval FDA Approves Kisqali (ribociclib) for HR+/HER2- Metastatic Breast Cancer |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.